Semaglutide vs Tirzepatide Mechanism of Action: How They Differ

One receptor versus two: what the pharmacology actually means

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide 1, a hormone released from the gut after eating. When semaglutide binds to GLP-1 receptors in the brain, pancreas and gut, it suppresses appetite signals, slows gastric emptying, and reduces post-meal blood-sugar spikes. These are well-characterised effects documented across the STEP clinical programme and reflected in the NHS semaglutide medicines page.

Tirzepatide adds a second target. It is a dual GIP and GLP-1 receptor agonist, activating the glucose-dependent insulinotropic polypeptide (GIP) pathway alongside GLP-1. GIP receptors are expressed in adipose tissue and the central nervous system. Activating both simultaneously appears to produce additive effects on appetite suppression and energy balance that neither pathway achieves alone. Tirzepatide is the only dual-agonist weight-loss medicine licensed in the UK.

For a broader look at how these molecular differences translate to the clinical experience, the Mounjaro vs Wegovy mechanism breakdown covers the receptor biology in more detail. The practical upshot is that the tirzepatide mechanism of action vs semaglutide involves a broader hormonal signal, which the trial evidence suggests drives somewhat greater average weight loss at top doses.

What the trial data shows — and where the head-to-head evidence sits

STEP 1 (68 weeks, semaglutide 2.4mg) reported approximately 15% average body-weight reduction versus placebo, published in the New England Journal of Medicine. SURMOUNT-1 (72 weeks, tirzepatide 15mg) reported approximately 20 to 21% average reduction. These trials used different populations and designs, so direct comparison from them alone is imprecise.

The clearest evidence on the tirzepatide vs semaglutide mechanism of action question in a clinical setting comes from SURMOUNT-5, a 72-week open-label head-to-head trial in 751 adults with obesity and no diabetes, published in the New England Journal of Medicine in 2025. Tirzepatide produced greater average weight reduction than semaglutide 2.4mg. NICE's appraisal of tirzepatide at TA1026 noted that indirect comparisons favour tirzepatide, consistent with SURMOUNT-5's findings.

The newer Wegovy 7.2mg maintenance dose (approved by the MHRA in January 2026 and available as a dedicated single-dose pen from April 2026) reported around 20.7% average weight loss over 72 weeks, which narrows the gap considerably. The Wegovy vs Mounjaro comparison page covers those specific figures. The bottom line: both medicines produce clinically meaningful weight loss; which mechanism suits a particular person depends on their medical history, not the trial averages alone.

Side-effect profiles shaped by the receptor difference

A question our prescribers hear most weeks: does tirzepatide's extra receptor make side effects worse? The short answer is that both medicines share a predominantly gastrointestinal profile, nausea, loose stools, constipation, indigestion, fatigue, because GLP-1 activation drives most of those effects in either case. The GIP component of tirzepatide may actually moderate some GI effects compared with a pure GLP-1 agonist at equivalent efficacy levels, though this is still being characterised.

Both medicines carry the same key warnings: inform your prescriber about a personal or family history of medullary thyroid carcinoma or MEN2, pancreatitis, or significant gastrointestinal conditions. The MHRA issued a Drug Safety Update in January 2026 reinforcing that acute pancreatitis, though infrequent, can be serious: severe stomach pain that radiates to the back warrants urgent medical attention. Any suspected side effects can be reported at the MHRA Yellow Card scheme.

Neither medicine is recommended during pregnancy, breastfeeding, or when actively trying to conceive, and neither is licensed for under-18s. Women on oral contraceptives starting tirzepatide should add a barrier method for the first four weeks and for four weeks after each dose increase, because gastric-emptying changes may reduce pill absorption. No equivalent interaction evidence exists for semaglutide. The detailed tirzepatide vs semaglutide comparison covers practical differences like this in full.

UK licensing, eligibility, and the private route

Both medicines are licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Tirzepatide (Mounjaro) is the only dual-agonist in this class; semaglutide (Wegovy) is the GLP-1-only option.

One important distinction: Ozempic is also semaglutide but is licensed exclusively for type 2 diabetes, not weight management. The Mounjaro vs Ozempic page explains why the two are not interchangeable. Similarly, Rybelsus oral semaglutide carries a diabetes licence, not a weight-loss one.

On the NHS, access follows phased NICE criteria and involves waiting lists. Private treatment through a GPhC-registered pharmacy lets you begin without a referral, subject to a prescriber confirming clinical suitability. The full tirzepatide vs semaglutide guide covers cost context, and the UK price comparison is useful if cost is a deciding factor for you.

Which mechanism is the right fit is a clinical decision our prescribers make with you. You can explore treatment options or go straight to a free consultation to start that conversation.